<DOC>
	<DOCNO>NCT01657019</DOCNO>
	<brief_summary>To evaluate safety tolerability SPD489 administer daily morning dose ( 50 70mg ) treatment moderate severe binge eat disorder ( BED ) adult</brief_summary>
	<brief_title>Open Label Extension Adults With Binge Eating Disorder ( BED )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Inclusion criterion : 1 . Completion antecedent SPD489 BED Doubleblind Study 2 . Subject meet follow Diagnostic Statistical Manual Mental Disorders Fourth Edition Text Revision ( DSMIVTR ) criteria diagnosis BED 3 . Subject body mass index ( BMI ) &gt; =18 &lt; =45 Exclusion criterion : 1 . Subject concurrent symptom bulimia nervosa anorexia nervosa . 2 . Subject consider suicide risk risk harm others</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>